

## **Injectpower receives €8.7m support from France 2030 to set up its micro battery production facility for implantable medical devices**

GRENOBLE, November 22, 2024 -- Injectpower is delighted to announce that this past summer it was selected as a winner of the "Industrialization and Health Capabilities 2030" call for projects under the France 2030 plan, operated by Bpifrance on behalf of the French government.

Injectpower develops, industrializes, and commercializes a new generation of solid-state, rechargeable micro batteries with high energy density and ultra-miniaturization, for implantable medical devices. Injectpower submitted an application in January 2024 for the establishment of a production plant for these innovative components in the heart of the French Silicon Valley, in the community of Villard-Bonnot, near Grenoble. The plant will be operational by mid-2026.

On average energy represents 80% of the volume of powered implants. Power is at the core of autonomous implantable medical devices, which are essential for improving therapeutic efficacy in monitoring and treatment of chronic diseases. The availability of new rechargeable, miniaturized energy storage solutions with longer lifetimes, such as those from Injectpower, will enable the emergence of a new class of medical solutions that are currently inaccessible.

The first applications proposed by Injectpower have been developed by its partner Injectsense Inc. These micro batteries will power ultra-thin pressure sensors in the eye and brain, respectively, to ensure continuous monitoring of pressure for the follow-up and treatment of glaucoma or hydrocephalus. The first solutions will reach the market starting in 2027. Other applications are also in development for cardiovascular pathologies (arterial pressure, cardiac rhythm), and neurostimulation (chronic pain, neurological diseases).

"We want to provide a breakthrough solution to a major and well-identified medical need that is not currently met by the technologies currently available on the market," said Philippe Andreucci, co-founder and CEO of Injectpower. "Our micro batteries will facilitate the development of new implanted devices to improve the lives of patients and better treat chronic diseases. Beyond our technical proposition, it is absolutely fundamental to be able to produce these products in a secure and sustainable manner. The First Factory funding is essential for the implementation of our future production tools and our market share in the field of medical devices. France 2030 is supporting our vision and local strategy for international deployment."

### **Contacts :**

Philippe ANDREUCCI - [philippe.andreucci@injectpwr.com](mailto:philippe.andreucci@injectpwr.com)

[www.injectpower.com](http://www.injectpower.com)